Global CT-Guided Biopsy Market Size, Share, and COVID-19 Impact Analysis, By Biopsy Technique (Core Needle Biopsy, Fine Needle Aspiration, Vacuum-Assisted, and Trephine or Bone), By End User (Hospitals, Imaging Centers, and ASCs), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035.

Global CT-Guided Biopsy Market Insights Forecasts to 2035

• The Global CT-Guided Biopsy Market Size Was Estimated at USD 882.2 Million in 2025
• The Market Size is Expected to Grow at a CAGR of around 5.4% from 2025 to 2035
• The Worldwide CT-Guided Biopsy Market Size is Expected to Reach USD 1573.2 Million by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, the global CT-Guided Biopsy market size was worth around USD 882.2 million in 2025 and is predicted to grow to around USD 1573.2 million by 2035 with a compound annual growth rate (CAGR) of 5.4% from 2025 to 2035. Technological developments, rising cancer incidence, developing minimally invasive treatments, expanding healthcare infrastructure in emerging nations, and growing need for precise, image-guided diagnostic solutions all present opportunities in the CT-guided biopsy market.

Market Overview

The worldwide market for specialized tools, supplies, and procedural processes used in needle-based tissue sampling performed under real-time or near-real-time Computed Tomography (CT) imaging guidance is included in the CT-guided biopsy market. Core needle biopsy systems, coaxial needles, fine-needle aspiration instruments, and sophisticated guiding platforms that work with conventional CT, CT-fluoroscopy, cone-beam CT, and newly developed spectral/dual-energy CT modalities are all included. Accurate localization of lesions in organs like the liver, lungs, and bones is made possible by CT-guided biopsy techniques, which improve diagnostic precision for diseases like cancer and infectious disorders.

In July 2025, Australia's National Lung Cancer Screening Program (NLCSP), which was launched, offers bulk-billed low-dose CT scans to high-risk persons aged 50–70, is one of the major government initiatives driving growth. It greatly increases the number of follow-up CT-guided biopsies performed for found nodules. One major factor is the growing prevalence of chronic illnesses and cancer, which raises the need for precise tissue diagnosis. The demand for confirmation biopsies is further fueled by the increasing use of imaging technology to identify worrisome lesions.

Report Coverage

This research report categorizes the CT-guided biopsy market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the CT-guided biopsy market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the CT-guided biopsy market.   

Driving Factors

Technological developments in CT imaging, such as dual-energy CT and CT-fluoroscopy, increase diagnostic yield and precision, which promotes adoption. The market is growing as a result of expanding cancer care pathways, which include repeat biopsies for treatment planning. Higher procedure volumes are also supported by expanding healthcare infrastructure and access to diagnostic services, particularly in developing nations like India. Additionally, because CT-guided biopsies lower surgical risks, recovery times, and hospital stays, there is a significant trend toward minimally invasive procedures.

Restraining Factors

High equipment and procedure costs, restricted access in low-resource areas, and dangers like radiation exposure and procedural problems are the main factors limiting the market for CT-guided biopsies. The lack of qualified specialists and the availability of alternative diagnostic techniques could further impede market expansion.

Market Segmentation

The CT-guided biopsy market share is classified into biopsy technique and end user.  

• The core needle biopsy segment dominated the market in 2025, approximately 58%, and is projected to grow at a substantial CAGR during the forecast period.  

Based on the biopsy technique, the CT-guided biopsy market is divided into core needle biopsy, fine needle aspiration, vacuum-assisted, and trephine or bone. Among these, the core needle biopsy segment dominated the market in 2025, approximately 58%, and is projected to grow at a substantial CAGR during the forecast period. The core needle biopsy segment, compared with other methods, can obtain larger tissue samples and has high diagnostic accuracy. Because it allows for accurate histological examination and minimizes the need for repeat procedures, this approach is highly favored in oncology. Patient safety and clinical efficiency are improved by its minimally invasive nature, quicker recovery, and lower complication rates.

• The hospitals segment accounted for the highest market revenue in 2025, approximately 72%, and is anticipated to grow at a significant CAGR during the forecast period.

Based on the end user, the CT-guided biopsy market is divided into hospitals, imaging centers, and ASCs. Among these, the hospitals segment accounted for the highest market revenue in 2025, approximately 72%, and is anticipated to grow at a significant CAGR during the forecast period. Hospitals have sophisticated imaging facilities, interdisciplinary teams, and the ability to carry out intricate, high-volume CT-guided biopsy procedures, particularly for deep-seated lesions and cancer diagnosis. Interventional radiology services are usually provided in hospitals, which contributes to their large revenue share.    

Regional Segment Analysis of the CT-Guided Biopsy Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the CT-guided biopsy market over the predicted timeframe.

North America is anticipated to hold the largest share of the CT-guided biopsy market over the predicted timeframe. Leading medical device manufacturers are well-represented in the area, and computed tomography system technology is constantly evolving. The U.S. National Cancer Institute's Screening Research Network, which enrolls thousands of people to assess multi-cancer detection assays that direct patient into CT-guided diagnostic pathways, and ongoing expansions in lung cancer screening programs that boost follow-up biopsy volumes are two significant government initiatives. Aidoc's comprehensive foundation model AI for abdomen CT triage, which improves procedural speed and accuracy in high-volume settings, and FDA certifications for sophisticated AI tools that identify numerous conditions from CT scans (January 2026) are two recent developments.  

Asia Pacific is expected to grow at a rapid CAGR in the CT-guided biopsy market during the forecast period. The demand for CT-guided biopsies is greatly increased by the region's sizable and expanding population as well as the rising rates of cancer and chronic disorders. The governments of nations like China, India, and Japan are actively improving healthcare spending and access, which encourages market growth. In addition to infrastructure expenditures that increase access to advanced imaging and biopsy services in tier-2 cities and private hospitals, notable government initiatives include extensive cancer screening programs and healthcare modernization projects in China and India.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the CT-guided biopsy market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Argon Medical Devices, Inc.
• Braun Melsungen AG
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Medical LLC
• Hologic, Inc.
• Medtronic plc
• Merit Medical Systems, Inc.
• Terumo Corporation
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

In February 2026, PGIMER launched PET/CT-guided prostate biopsy, achieving a 95% diagnostic success rate with a single puncture. The technique reduces rectal exposure and infections, enhancing precision and minimizing repeat procedures in prostate cancer diagnostics.

In September 2025, Merit Medical launched its semi-automatic TEMNO Elite and full-core CorVocet biopsy needles in Japan. TEMNO Elite produced the heaviest specimens, while CorVocet achieved higher sample weight with longer throws, supporting improved core sampling yields.

In July 2025, researchers announced VERITAS trial results showing navigational bronchoscopy is noninferior to CT-guided TTNB for peripheral lung nodules, delivering comparable accuracy with significantly fewer complications, including a much lower pneumothorax rate.

In May 2025, Hologic announced the Brevera Breast Biopsy System 7-gauge needle launch in Europe, expanding disposable needle options and enhancing vacuum-assisted breast biopsy procedures with integrated tissue acquisition, imaging, and post-biopsy verification.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the CT-guided biopsy market based on the below-mentioned segments: 

Global CT-Guided Biopsy Market, By Biopsy Technique

• Core Needle Biopsy
• Fine Needle Aspiration
• Vacuum-assisted
• Trephine or Bone

Global CT-Guided Biopsy Market, By End User

• Hospitals
• Imaging Centers
• ASCs

Global CT-Guided Biopsy Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa